Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flow cytometric immunophenotyping for hematologic neoplasms.

Fiona E Craig1, Kenneth A Foon

  • 1Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, PA, USA. craigfe@upmc.edu

Blood
|January 17, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flow cytometric detection of clonal T-cell populations in CAR T-cell therapy related enteropathy.

Leukemia & lymphoma·2026
Same author

Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.

Cell reports. Medicine·2024
Same author

Rapid Expansion of a Teledermatology Web Application for Digital Dermatology Assessment Necessitated by the COVID-19 Pandemic: Retrospective Evaluation.

JMIR dermatology·2023
Same author

Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Mayo Clinic Clinical and Pathologic Study.

Archives of pathology & laboratory medicine·2023
Same author

Rare Multisystem Histiocytic Sarcoma on <sup>18</sup>F-FDG PET/CT.

Journal of nuclear medicine technology·2021
Same author

Primary cutaneous CD4<sup>+</sup> small/medium T-cell lymphoproliferative disorder: Diagnosis and management.

Journal of the American Academy of Dermatology·2021
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Flow cytometric immunophenotyping is crucial for diagnosing and monitoring blood cancers. Advances in technology enhance the identification of abnormal cells, aiding in precise classification and treatment guidance.

Area of Science:

  • Hematology
  • Immunology
  • Molecular Biology

Background:

  • Flow cytometric immunophenotyping is essential for diagnosing, classifying, staging, and monitoring hematologic neoplasms.
  • Recent advancements in instrumentation, antibodies, and fluorochromes have improved the detection of abnormal cell populations.

Purpose of the Study:

  • To review the current applications of flow cytometric immunophenotyping in hematologic neoplasms.
  • To discuss how flow cytometry data aids in diagnosis and directs further testing.

Main Methods:

  • Review of recent literature and clinical guidelines.
  • Discussion of multiparametric approaches integrating morphology, immunophenotype, and genotype.
  • Incorporation of recommendations from the Bethesda International Consensus Conference.

Related Experiment Videos

Main Results:

  • Phenotypic abnormalities are documented in various hematologic neoplasms.
  • The 2001 World Health Organization (WHO) classification emphasizes a multiparametric diagnostic approach.
  • Consensus conferences provide guidelines for the medical indications of flow cytometric testing.

Conclusions:

  • Flow cytometry is indispensable for hematologic neoplasm management.
  • Improved technology enhances sensitivity for detecting minimal disease.
  • Standardized criteria and consensus guidelines refine diagnostic accuracy and clinical application.